| Not Yet Recruiting | A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV NCT07010822 | Fidec Corporation | Phase 3 |
| Recruiting | Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vacci NCT07457060 | Sinovac Biotech Co., Ltd | Phase 4 |
| Recruiting | Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation NCT06895486 | PATH | Phase 2 |
| Recruiting | Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations NCT07354269 | Sinovac Biotech Co., Ltd | Phase 4 |
| Recruiting | A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid NCT06947499 | LG Chem | Phase 2 / Phase 3 |
| Completed | The Impact of 'Digital Strolling' on Depression and Quality of Life of People With Severe Mobility Impairment NCT07073144 | The Hong Kong Polytechnic University | N/A |
| Recruiting | A Study to Evaluate the Safety and Immunogenicity of VLP-Polio in Infants and Toddlers NCT06577298 | CanSino Biologics Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines NCT06137664 | PATH | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healt NCT06618196 | LG Chem | Phase 2 |
| Completed | Booster Dose of sIPV Co-administered With MMR and HepA-I. NCT06442449 | Sinovac Biotech Co., Ltd | Phase 4 |
| Completed | Sequential Vaccination of Poliomyelitis Vaccine (Vero Cells), Inactivated, Sabin Strains From Different Manufa NCT06346834 | Sinovac Biotech Co., Ltd | Phase 4 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) NCT06101173 | CanSino Biologics Inc. | Phase 1 |
| Unknown | Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama NCT05654467 | PATH | Phase 2 |
| Completed | A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2 NCT05677256 | Fidec Corporation | Phase 4 |
| Completed | High Intensity Functional Training for Individuals With Neurologic Diagnoses and Their Care Partners NCT05951985 | Arkansas Colleges of Health Education | N/A |
| Unknown | A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults NCT05952596 | LG Chem | Phase 1 |
| Completed | A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine NCT05850364 | Sinovac Biotech Co., Ltd | Phase 3 |
| Unknown | Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Prima NCT05457946 | LG Chem | Phase 2 / Phase 3 |
| Recruiting | Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh NCT05644184 | PATH | Phase 2 |
| Completed | A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vac NCT06752174 | Beijing Minhai Biotechnology Co., Ltd | Phase 3 |
| Completed | Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose i NCT05431933 | LG Chem | Phase 3 |
| Completed | Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intrader NCT05460377 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants NCT05432141 | Sinovac Biotech Co., Ltd | Phase 4 |
| Unknown | Physical Activity in People With Sequelae of Poliomyelitis NCT05303545 | Institut de Sante Parasport Connecte Synergies | — |
| Unknown | Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT NCT05327426 | University of Vermont | Phase 1 |
| Completed | Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed In NCT05163561 | Serum Institute of India Pvt. Ltd. | Phase 3 |
| Completed | Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants NCT05033561 | Fidec Corporation | Phase 3 |
| Completed | An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses NCT04989231 | Sinovac Biotech Co., Ltd | — |
| Completed | Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines NCT04529538 | PATH | Phase 1 |
| Completed | Immunogenicity nOPV2 With and Without bOPV NCT04579510 | Centers for Disease Control and Prevention | Phase 2 |
| Withdrawn | Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine a NCT05166031 | Fidec Corporation | Phase 3 |
| Completed | Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®) NCT04448132 | AJ Vaccines A/S | Phase 4 |
| Completed | Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenic NCT05386810 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in Chin NCT04614597 | Centers for Disease Control and Prevention, China | — |
| Completed | Effect of Lactoferrin on Polio Seroconversion NCT04432935 | Aga Khan University | N/A |
| Completed | Clinical Trial of Novel OPV2 Vaccine NCT04693286 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 2 |
| Completed | Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine NCT04386707 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | Effect of Ankle-foot Orthoses on Balance Confidence NCT04080687 | University Rehabilitation Institute, Republic of Slovenia | — |
| Unknown | To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Child NCT04618640 | Boryung Biopharma Co., Ltd. | Phase 3 |
| Unknown | Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants NCT04073459 | LG Chem | Phase 2 |
| Terminated | Immunogenicity of Intramuscular and Intradermal IPV NCT04063150 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Im NCT04618783 | Sinovac Biotech Co., Ltd | N/A |
| Completed | Confirmatory Study of BK1310 in Healthy Infants NCT03891758 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study NCT03722004 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine NCT03554798 | Fidec Corporation | Phase 2 |
| Completed | Persistence of IPV Immunity NCT03723837 | Tribhuvan University Teaching Hospital, Institute Of Medicine. | Phase 4 |
| Completed | A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates NCT04544787 | Pierre Van Damme | Phase 2 |
| Unknown | Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administere NCT03890497 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 4 |
| Completed | A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in NCT03822767 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in NCT03822754 | Sinovac Biotech Co., Ltd | Phase 3 |
| Completed | A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China. NCT03597919 | Centers for Disease Control and Prevention, China | Phase 4 |
| Completed | Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China NCT03546634 | Centers for Disease Control and Prevention, China | Phase 4 |
| Completed | Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 NCT03671616 | Statens Serum Institut | Phase 3 |
| Completed | Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain NCT04224519 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 4 |
| Completed | Inactivated Poliomyelitis Vaccine Made From Sabin Strain NCT04220515 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 4 |
| Unknown | Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine NCT03821441 | Chinese Academy of Medical Sciences | Phase 3 |
| Withdrawn | Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at NCT03128489 | GlaxoSmithKline | Phase 3 |
| Completed | Duration of IPV Priming and Antibody Decay NCT03202719 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV NCT03239496 | Fidec Corporation | Phase 3 |
| Completed | Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell) NCT07297186 | Beijing Minhai Biotechnology Co., Ltd | Phase 3 |
| Completed | An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants NCT03526978 | Sinovac Biotech Co., Ltd | Phase 3 |
| Unknown | Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan NCT03286803 | Aga Khan University | Phase 4 |
| Completed | A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults NCT03208101 | LG Chem | Phase 1 |
| Withdrawn | A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine NCT03016949 | Fidec Corporation | Phase 3 |
| Terminated | IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults NCT03092791 | Takeda | Phase 1 / Phase 2 |
| Completed | A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Inf NCT03169725 | LG Chem | Phase 2 / Phase 3 |
| Completed | Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Ad NCT03430349 | Pierre Van Damme | Phase 1 |
| Completed | A Campaign-based ID fIPV Administration Trial NCT02967783 | Medical Research Council Unit, The Gambia | N/A |
| Completed | Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 NCT03032419 | Statens Serum Institut | Phase 3 |
| Completed | Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age NCT03025750 | Statens Serum Institut | Phase 3 |
| Completed | Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine NCT02985320 | Sinovac Biotech Co., Ltd | Phase 1 / Phase 2 |
| Completed | Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers NCT02853929 | GlaxoSmithKline | Phase 4 |
| Completed | Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study NCT02847026 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ NCT02422264 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine NCT02643368 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuani NCT02582255 | Fidec Corporation | Phase 4 |
| Completed | A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age NCT02580201 | Fidec Corporation | Phase 4 |
| Completed | Safety and Immunogenicity of IPOVAC in Young Children NCT02775942 | National Institute of Hygiene and Epidemiology, Vietnam | Phase 2 |
| Completed | Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV NCT03614702 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 3 |
| Completed | Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine NCT02643446 | Centers for Disease Control and Prevention, China | — |
| Completed | Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine NCT02434770 | PATH | Phase 3 |
| Completed | Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 NCT02428491 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus NCT02785705 | Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control | Phase 3 |
| Completed | Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules NCT02412514 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS NCT02458183 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Completed | 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infan NCT02347423 | Statens Serum Institut | Phase 2 |
| Completed | Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine NCT02291263 | Centers for Disease Control and Prevention | Phase 3 |
| Completed | DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Ja NCT02274285 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Polio End-game Strategies - Poliovirus Type 2 Challenge Study NCT02189811 | Aga Khan University | Phase 4 |
| Completed | Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 a NCT02096263 | GlaxoSmithKline | Phase 3 |
| Completed | DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed NCT02094833 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Active Not Recruiting | Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control O NCT02089880 | Shirley Ryan AbilityLab | N/A |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccin NCT01948193 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan NCT02005536 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus NCT01997632 | University Hospital, Ghent | Phase 1 |
| Completed | Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa NCT01983540 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | IPV Clinical Trial - The Gambia NCT01847872 | London School of Hygiene and Tropical Medicine | Phase 4 |
| Unknown | Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns NCT01870206 | Laboratorios de Biologicos y Reactivos de México, S.A. de C.V. | Phase 3 |
| Completed | Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine NCT01831050 | Fidec Corporation | Phase 4 |
| Terminated | Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer NCT01751503 | Iva Hauptmannova | N/A |
| Completed | Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers NCT01577732 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity of Inactivated and Live Polio Vaccines NCT01813604 | Centers for Disease Control and Prevention | Phase 3 |
| Completed | Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea NCT01568060 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) V NCT01353703 | GlaxoSmithKline | Phase 3 |
| Completed | Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE) NCT01571505 | International Vaccine Institute | Phase 1 |
| Completed | Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants NCT01709071 | Pauline Verdijk | Phase 1 / Phase 2 |
| Completed | Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE NCT01546909 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV) NCT01510366 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 3 |
| Completed | Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis NCT01475539 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/H NCT01453998 | GlaxoSmithKline | Phase 2 |
| Completed | Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Health NCT01444781 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults NCT01708720 | Pauline Verdijk | Phase 1 |
| Completed | Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan NCT01389687 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Regulatory Post-Marketing Surveillance Study for TETRAXIM™ NCT01437423 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/H NCT01358825 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers NCT01323647 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children NCT01245049 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults NCT01323959 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine NCT01309646 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEV NCT01287949 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell) NCT02231632 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 2 / Phase 3 |
| Completed | Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217 NCT01248884 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Childre NCT01094171 | GlaxoSmithKline | Phase 4 |
| Completed | A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China NCT01278433 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | A Study of the Safety of IMOVAX Polio™ in China NCT01244464 | Sanofi | Phase 4 |
| Completed | Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, NCT01249183 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. NCT01214889 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster NCT01171989 | GlaxoSmithKline | Phase 2 |
| Completed | A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants NCT01177722 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants NCT01090453 | GlaxoSmithKline | Phase 2 |
| Completed | Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan NCT01229579 | Aga Khan University | N/A |
| Completed | Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vac NCT01105559 | Sanofi | — |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine NCT01086423 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) NCT00964028 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age NCT01031303 | Sanofi | Phase 4 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine NCT01021293 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Month NCT00970307 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants NCT00937404 | GlaxoSmithKline | Phase 1 |
| Completed | The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV) NCT01056705 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers NCT00920439 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. NCT00871000 | GlaxoSmithKline | Phase 3 |
| Terminated | Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months NCT00871741 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly NCT00885157 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of Adacel Polio Vaccine NCT00797511 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants NCT00753649 | GlaxoSmithKline | Phase 4 |
| Completed | The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains NCT01048190 | Chinese Academy of Medical Sciences | Phase 1 |
| Completed | Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infan NCT00654901 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Chil NCT00611559 | GlaxoSmithKline | Phase 4 |
| Completed | Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine NCT00635128 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine NCT00627458 | GlaxoSmithKline | Phase 2 |
| Completed | Quality of Life in Adult Neurological Patients NCT01573936 | Associação de Assistência a Criança Deficiente | N/A |
| Completed | Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly NCT00604058 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children NCT00514033 | GlaxoSmithKline | — |
| Completed | Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccin NCT00463437 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months NCT00453570 | Sanofi | Phase 3 |
| Completed | REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children NCT00447525 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) NCT00432042 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants NCT00404651 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL NCT00355121 | Sanofi | Phase 2 |
| Completed | Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age NCT00376779 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and To NCT00343421 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV NCT00348387 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combin NCT00337428 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Health NCT00320463 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV NCT00319852 | Sanofi | Phase 3 |
| Completed | Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine NCT00304265 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentine NCT00303316 | Sanofi | Phase 3 |
| Completed | Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule NCT00287092 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand NCT00255021 | Sanofi | Phase 4 |
| Completed | Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Sch NCT00316147 | GlaxoSmithKline | Phase 3 |
| Completed | Pentavalent DTaP-Hep B-IPV NCT00133445 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjuga NCT00307567 | GlaxoSmithKline | Phase 2 |
| Completed | Safety of Imovax Polio in Chinese Infants and Children NCT00258843 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of Pentaxim in South African Infants NCT00254969 | Sanofi | Phase 3 |
| Completed | Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Health NCT00325156 | GlaxoSmithKline | Phase 4 |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinea NCT00831311 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis NCT00325143 | GlaxoSmithKline | Phase 3 |
| Completed | Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccinati NCT01457547 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months NCT00352963 | GlaxoSmithKline | Phase 3 |
| Completed | Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine NCT00137696 | Centers for Disease Control and Prevention | N/A |
| Completed | Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine NCT00146835 | GlaxoSmithKline | — |
| Completed | Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) NCT00092469 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infa NCT00879827 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vacc NCT01457560 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separatel NCT01457508 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Pol NCT02040636 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly NCT01457495 | GlaxoSmithKline | Phase 2 |
| Completed | Study of "Post-Polio Syndrome" NCT00001185 | National Institute of Neurological Disorders and Stroke (NINDS) | — |
| Completed | Pilot Study Freeze and Transport Immune Cells NCT00138268 | National Institute of Allergy and Infectious Diseases (NIAID) | — |